April 2011
Volume 52, Issue 14
Free
ARVO Annual Meeting Abstract  |   April 2011
Nonclinical Assessment of the Effect of Taprenepag Isopropyl (PF-04217329) Formulated With and Without Benzylkonium Chloride (BAC) and Xalatan® on Intraocular Exposure of the Active Metabolites of Taprenepag (CP-544326) and Xalatan® (Latanoprost Acid)
Author Affiliations & Notes
  • Michael H. Shiue
    Pharmacokinetics, Dynamics, & Metabolism,
    Pfizer Inc, San Diego, California
  • B Jessen
    Drug Safety R & D,
    Pfizer Inc, San Diego, California
  • S Raber
    Clinical Pharmacology,
    Pfizer Inc, San Diego, California
  • R A. Schachar
    Ophthalmology,
    Pfizer Inc, San Diego, California
  • J Shah
    Pharmaceutical Sciences,
    Pfizer Inc, San Diego, California
  • D Arenson
    Pharmaceutical Sciences,
    Pfizer Inc, San Diego, California
Investigative Ophthalmology & Visual Science April 2011, Vol.52, 1520. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      Michael H. Shiue, B Jessen, S Raber, R A. Schachar, J Shah, D Arenson; Nonclinical Assessment of the Effect of Taprenepag Isopropyl (PF-04217329) Formulated With and Without Benzylkonium Chloride (BAC) and Xalatan® on Intraocular Exposure of the Active Metabolites of Taprenepag (CP-544326) and Xalatan® (Latanoprost Acid). Invest. Ophthalmol. Vis. Sci. 2011;52(14):1520.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose: : To evaluate potential additive effects of taprenepag (with and without BAC) and Xalatan® on intraocular exposures of CP-544326 and latanoprost acid during mono and combination applications of the drugs. The results would clarify if the increase in side effects seen in the FIH Phase 2 clinical trial of topical taprenepag alone and in an unfixed combination with Xalatan® in ocular hypertensive and primary open angle subjects was due to the combination effect of preservative from both formulations.

Methods: : Dutch belted pigmented rabbits (N=100) were topically dosed with taprenepag formulated in the presence and absence of BAC and/or Xalatan® in various sequence and durations. The rabbits were sacrificed at predetermined time points and the exposure levels of CP-544326 and/or latanoprost acid were measured in cornea, aqueous humor, and plasma. The collected samples were analyzed by LC-MS/MS methods. All rabbit studies were conducted in accordance with the guidelines of the ARVO Statement for the Use of Animals in Ophthalmic and Vision Research.

Results: : Neither CP-544326 nor latanoprost acid exposures were significantly affected by taprenepag containing or not containing BAC, the order of the combination treatment, or multiday dosing. The concentration of CP-544326 and latanoprost acid in plasma samples from all treatment conditions were below the limits of quantitation of 0.2 and 0.1 ng/mL, respectively.

Conclusions: : The current investigation suggests that ocular surface exposure to taprenepag formulated in the presence or absence of BAC and/or Xalatan® does not increase the intraocular exposure of CP-544326 or latanoprost acid. Therefore, it is unlikely that the observed clinical AEs were due to elevated absorption of the metabolites of the prodrugs.

Keywords: drug toxicity/drug effects 
×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×